(VOX) Voxel S.A. - Ratings and Ratios
Biostimulators, Collagen, Filler Implants, Mesotherapy Supplies
Description: VOX Voxel S.A.
Voxel S.A. (WAR:VOX) is a Polish biotechnology company whose common stock is being analyzed for potential trading opportunities. The companys market capitalization stands at approximately 1837.95 million PLN, indicating a significant presence in the market.
Key performance indicators (KPIs) suggest that Voxel S.A. is operating efficiently, with a Return on Equity (RoE) of 29.36%, which is a relatively high figure indicating strong profitability. The Price-to-Earnings (P/E) ratio is 18.21, and the forward P/E is 17.39, suggesting that the stock may be reasonably valued compared to its earnings potential.
The biotechnology industry is driven by several key economic factors, including research and development (R&D) expenditure, government regulations, and the demand for innovative medical solutions. Companies in this sector often experience significant growth due to the development of new treatments and technologies. Voxel S.A.s performance is likely influenced by these factors, and its ability to navigate the complex regulatory landscape will be crucial to its future success.
From a trading perspective, the stock has shown a strong upward trend, with the 50-day Simple Moving Average (SMA) at 167.78 and the 200-day SMA at 142.77, indicating a significant increase in value over time. The Average True Range (ATR) is 5.00, or 2.79% of the last price, suggesting moderate volatility. The beta of 0.585 indicates that the stock is relatively less volatile than the overall market, making it potentially attractive to risk-averse investors.
To further evaluate the trading opportunity, it is essential to consider additional KPIs, such as revenue growth, gross margin, and operating cash flow. Analyzing these metrics will provide a more comprehensive understanding of Voxel S.A.s financial health and growth prospects, enabling more informed investment decisions.
VOX Stock Overview
| Market Cap in USD | 510m |
| Sub-Industry | Biotechnology |
| IPO / Inception |
VOX Stock Ratings
| Growth Rating | 95.6% |
| Fundamental | 87.1% |
| Dividend Rating | 66.9% |
| Return 12m vs S&P 500 | 54.8% |
| Analyst Rating | - |
VOX Dividends
| Dividend Yield 12m | 1.80% |
| Yield on Cost 5y | 8.28% |
| Annual Growth 5y | 25.03% |
| Payout Consistency | 94.5% |
| Payout Ratio | 37.0% |
VOX Growth Ratios
| Growth Correlation 3m | 77.4% |
| Growth Correlation 12m | 95.9% |
| Growth Correlation 5y | 84.4% |
| CAGR 5y | 38.69% |
| CAGR/Max DD 5y | 1.04 |
| Sharpe Ratio 12m | -0.13 |
| Alpha | 72.13 |
| Beta | 0.235 |
| Volatility | 27.89% |
| Current Volume | 1.6k |
| Average Volume 20d | 1.6k |
| Stop Loss | 164.9 (-3.1%) |
| Signal | -0.40 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (101.5m TTM) > 0 and > 6% of Revenue (6% = 33.4m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA -6.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.01% (prev 17.62%; Δ -3.61pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.19 (>3.0%) and CFO 116.6m > Net Income 101.5m (YES >=105%, WARN >=100%) |
| Net Debt (3.24m) to EBITDA (111.2m) ratio: 0.03 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.68 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (10.5m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 28.84% (prev 34.55%; Δ -5.70pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 95.69% (prev 79.31%; Δ 16.38pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 11.50 (EBITDA TTM 111.2m / Interest Expense TTM 9.67m) >= 6 (WARN >= 3) |
Altman Z'' 4.86
| (A) 0.12 = (Total Current Assets 192.7m - Total Current Liabilities 114.7m) / Total Assets 626.6m |
| (B) 0.46 = Retained Earnings (Balance) 285.5m / Total Assets 626.6m |
| (C) 0.19 = EBIT TTM 111.2m / Avg Total Assets 582.1m |
| (D) 1.21 = Book Value of Equity 285.5m / Total Liabilities 235.3m |
| Total Rating: 4.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 87.09
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 2.32% = 1.16 |
| 3. FCF Margin 7.77% = 1.94 |
| 4. Debt/Equity 0.09 = 2.50 |
| 5. Debt/Ebitda 0.32 = 2.42 |
| 6. ROIC - WACC 16.78% = 12.50 |
| 7. RoE 29.36% = 2.45 |
| 8. Rev. Trend 92.17% = 4.61 |
| 9. Rev. CAGR 30.37% = 2.50 |
| 10. EPS Trend 80.85% = 2.02 |
| 11. EPS CAGR 83.60% = 2.50 |
What is the price of VOX shares?
Over the past week, the price has changed by -2.74%, over one month by -5.97%, over three months by +9.81% and over the past year by +81.85%.
Is Voxel S.A. a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VOX is around 222.60 PLN . This means that VOX is currently undervalued and has a potential upside of +30.79% (Margin of Safety).
Is VOX a buy, sell or hold?
What are the forecasts/targets for the VOX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 151.9 | -10.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 244.6 | 43.7% |
VOX Fundamental Data Overview
Market Cap PLN = 1.87b (1.87b PLN * 1.0 PLN.PLN)
CCE Cash And Equivalents = 32.4m PLN (Cash only, last quarter)
P/E Trailing = 18.4041
P/E Forward = 17.4825
P/S = 3.3489
P/B = 4.8251
Beta = 0.466
Revenue TTM = 557.0m PLN
EBIT TTM = 111.2m PLN
EBITDA TTM = 111.2m PLN
Long Term Debt = 1.02m PLN (from longTermDebt, last quarter)
Short Term Debt = 34.6m PLN (from shortLongTermDebt, last quarter)
Debt = 35.6m PLN (Calculated: Short Term 34.6m + Long Term 1.02m)
Net Debt = 3.24m PLN (from netDebt column, last quarter)
Enterprise Value = 1.87b PLN (1.87b + Debt 35.6m - CCE 32.4m)
Interest Coverage Ratio = 11.50 (Ebit TTM 111.2m / Interest Expense TTM 9.67m)
FCF Yield = 2.32% (FCF TTM 43.3m / Enterprise Value 1.87b)
FCF Margin = 7.77% (FCF TTM 43.3m / Revenue TTM 557.0m)
Net Margin = 18.22% (Net Income TTM 101.5m / Revenue TTM 557.0m)
Gross Margin = 28.84% ((Revenue TTM 557.0m - Cost of Revenue TTM 396.3m) / Revenue TTM)
Tobins Q-Ratio = 6.55 (Enterprise Value 1.87b / Book Value Of Equity 285.5m)
Interest Expense / Debt = 7.72% (Interest Expense 2.75m / Debt 35.6m)
Taxrate = 18.27% (from yearly Tax Provision: 21.9m / 119.6m)
NOPAT = 90.9m (EBIT 111.2m * (1 - 18.27%))
Current Ratio = 1.68 (Total Current Assets 192.7m / Total Current Liabilities 114.7m)
Debt / Equity = 0.09 (Debt 35.6m / last Quarter total Stockholder Equity 384.8m)
Debt / EBITDA = 0.32 (Net Debt 3.24m / EBITDA 111.2m)
Debt / FCF = 0.82 (Debt 35.6m / FCF TTM 43.3m)
Total Stockholder Equity = 345.7m (last 4 quarters mean)
RoA = 16.20% (Net Income 101.5m, Total Assets 626.6m )
RoE = 29.36% (Net Income TTM 101.5m / Total Stockholder Equity 345.7m)
RoCE = 32.07% (Ebit 111.2m / (Equity 345.7m + L.T.Debt 1.02m))
RoIC = 23.65% (NOPAT 90.9m / Invested Capital 384.2m)
WACC = 6.87% (E(1.87b)/V(1.90b) * Re(6.88%)) + (D(35.6m)/V(1.90b) * Rd(7.72%) * (1-Tc(0.18)))
Discount Rate = 6.88% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 76.71% ; FCFE base≈55.0m ; Y1≈49.7m ; Y5≈43.0m
Fair Price DCF = 73.99 (DCF Value 777.1m / Shares Outstanding 10.5m; 5y FCF grow -11.97% → 3.0% )
Revenue Correlation: 92.17 | Revenue CAGR: 30.37%
Rev Growth-of-Growth: 8.90
EPS Correlation: 80.85 | EPS CAGR: 83.60%
EPS Growth-of-Growth: -40.73